Geron Corporation (GERN)

Market Cap	695.44M
Revenue (ttm)	183.40M
Net Income (ttm)	-79.99M
Shares Out	638.02M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,738,730
Open	1.100
Previous Close	1.150
Day's Range	1.040 - 1.140
52-Week Range	1.040 - 4.500
Beta	0.56
Analysts	Buy
Price Target	3.00 (+175.23%)
Earnings Date	Nov 5, 2025

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 175.23% from the latest price.

Price Target

$3.0

(175.23% upside)

Analyst Consensus: Buy